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Abstract 
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening disease characterized by 
hyperactivation of the immune system that causes hypercytokinemia and potentially multi organ failure. HLH can 
occur in patients with underlying rheumatic or autoinflammatory disorders. Additionally, HLH can develop in patients 
during infections or malignancies without a known genetic predisposition.
Case presentation: We herein report a patient, who presented with fever, both acute kidney and liver injury, anemia, 
thrombocytopenia and HSV stomatitis. HLH was diagnosed based on clinical criteria and qPCR revealed an acute par-
vovirus B19 infection as potential underlying infectious trigger. Treatment was started with both IVIG and dexametha-
sone. Subsequently, kidney biopsy demonstrated TMA.
Conclusions: In rare cases both HLH and aHUS can occur simultaneously in a patient as a consequence of viral infec-
tions. Insights from this unusual case might help physicians understand this complex symptom constellation.
Keywords: Hemophagocytic Lymphohistiocytosis (HLH), Atypical hemorrhagic uremic syndrome (aHUS), Parvovirus 
B19, Case report
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Background
Hemophagocytic lymphohistiocytosis (HLH) is a rare 
clinical condition (1/800000 adults per year, 1–10/Mil-
lion children per year) with excessive immune activation 
and inflammation, eventually leading to multi organ fail-
ure. It can be divided into primary (genetic) forms which 
mostly affect children and secondary forms which are 
subclassified as viral, autoimmune, or paraneoplastic [1, 
2].
Thrombotic microangiopathies (TMA) are a group 
of disorders characterized by microthrombi causing 
microangiopathic hemolytic anemia, thrombocytopenia 
and ischemic tissue injury [3]. TMAs encompass primary 
forms which occur spontaneously and secondary forms 
which develop in the context of pregnancy, autoimmune 
disease, malignancy, infection, malignant hypertension, 
bone marrow transplantation or the use of certain medi-
cations [4].
Here we report a case of simultaneous HLH and TMA 
after acute infection with parvovirus B19 (PVB19) in a 
kidney transplant recipient.
Case presentation
In September 2020, a 50-year-old female was admitted to 
our hospital with PCR-diagnosed HSV-1 stomatitis and 
refractory anemia. The patient had received a cadaveric 
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donor kidney transplantation for kidney failure due to 
IgA vasculitis in 2007 and was on triple immunosup-
pressive therapy including prednisolone (2.5 mg daily), 
mycophenolate mofetil (1500 mg daily) and cyclosporine 
A (100 mg daily). Laboratory testing on admission 
showed chronic allograft dysfunction (creatinine 3.1 mg/
dl), anemia (Hb 5.9 g/dl) with low reticulocytes (32/nl) 
and low markers of systemic inflammation (CRP 1.9 mg/l, 
ferritin 324 μg/l). Transferrin saturation, vitamin B12 and 
folic acid levels, cyclosporine A through concentrations 
(48 ng/ml) as well as haptoglobin were within the normal 
range. There was no clinical sign of blood loss. Serum 
PCR-testing was negative for HSV-1/2, varicella zoster, 
CMV, EBV, HIV and parvovirus B19 (PVB19) respec-
tively. A nasopharyngeal swab for SARS-CoV-2 was 
negative.
The patient was initially treated with intravenous acy-
clovir for 14 days, and immunosuppression was reduced 
by pausing mycophenolate mofetil and reducing cyclo-
sporine A. Reticulocytes and hemoglobin levels recov-
ered consequently and stomatitis resolved.
Eleven days after admission the patient suddenly devel-
oped fever up to 40 °C, low oxygen saturation (92%) and 
a cough. The lab results indicated acute on chronic allo-
graft dysfunction (creatinine 4.1 mg/dl), acute hepatitis 
(ASAT 249 U/l, ALAT 300 U/l, bilirubin 4.1 mg/dl), mod-
erately elevated CRP (29 mg/l) and an extremely high fer-
ritin level (20,659 μg/l). Additionally, the patient showed 
thrombocytopenia (92/μl), elevated LDH (1170 U/l) 
and reduced haptoglobin (< 0.1 g/l), elevated d-dimer 
(8.8 mg/l), elevated soluble IL-2 receptor (12,458 IU/ml), 
elevated triglycerides (255 mg/dl) and low fibrinogen 
(1.0 g/l), reduced C3 and C4 (620 and 140 mg/l respec-
tively). Coombs test was negative and a blood smear 
was negative for schistocytes. A chest CT scan ruled 
out pneumonia and pulmonary embolism. Abdominal 
ultrasound revealed ascites and moderate splenomegaly. 
Multiple urine and blood cultures did not show bacterial 
infection. A second PCR for SARS-CoV-2 was negative.
The diagnosis of hemophagocytic lymphohistiocytosis 
(HLH) was made based on the patient’s extremely high 
ferritin levels, presence of 6 out of 8 HLH diagnostic cri-
teria and an HScore of 269 indicating a 99% probability 
of HLH. Treatment with dexamethasone 20 mg daily was 
started on day 13. Bone marrow aspiration and biopsy 
were conducted on day 14 and revealed no pathological 
findings (no evidence of HLH).
Fever subsided 1 day after starting dexamethasone, 
kidney function improved, and the levels of ferritin, 
transaminases and bilirubin decreased.
PCR for hepatitis B, C, D and E as well as for EBV 
and CMV were negative. Repeated PCR testing for 
PVB19 revealed > 10 million copies/ml. Treatment with 
intravenous immunoglobulins (100 g cumulative) was 
started over a course of 3 days to address the PVB19 
infection. Dexamethasone dose was tapered to 8 mg on 
the day of discharge. PCR testing of the bone marrow 
sample revealed > 9 million copies/ml of PVB19. Sero-
logic testing of blood samples was positive for IgM and 
negative IgG suggesting primary infection with PVB19.
In the following days the patient’s condition further 
improved, the viral load fell to 16,400 copies/ml at the 
time of discharge and ferritin levels decreased to 298 μg/l.
On day 35, the patient was re-admitted after a hyper-
tensive crisis and a suspected seizure. Magnetic reso-
nance imaging of the brain (including diffusion weighted 
imaging and fluid-attenuated inversion recovery 
sequences) as well as EEG did not show any pathological 
findings (e.g. posterior reversible leukoencephalopathy 
syndrome, intracranial hemorrhage). Laboratory testing 
showed worsening hemolysis, thrombocytopenia, com-
plement consumption, schistocytes of 0.1% and further 
increasing albuminuria (UACR > 5 g/g). Ferritin, serum 
albumin levels and cyclosporine A through concentra-
tions (40 ng/ml) were within the normal range and cre-
atinine was stable at the patient’s previous baseline 
concentration. A renal allograft biopsy was performed, 
which showed glomerular TMA without vascular rejec-
tion, glomerulitis or peritubular capillaritis as well as 
tubular atrophy and 20% interstitial fibrosis (Fig.  1). 
ADAMTS13 diagnostic ruled out a TTP. On a follow up 
visit in our outpatient clinic on day 48 the patient was in 
good clinical condition. Ferritin was within the normal 
range and albuminuria was decreasing (UPCR 1.5 g/g), 
creatinine concentration was 3,5 mg/dl. Considering the 
gradual improvement we decided against therapeutic 
plasma exchange and complement inhibiting therapy 
Table 1.
The clinical course, lab values and treatment are 
depicted in Fig.  2. Genetic screening did not reveal a 
pathogenic variant in complement genes. However the 
patient revealed to be homozygous for the known CFH-
H3 (alias  CFHtgtgt) risk haplotye as well as heterozygous 
carrier of the CFHR1*B risk allele.
Discussion and conclusion
In the present case, suspicion for HLH was raised by oth-
erwise unexplained multi organ failure and extremely 
high ferritin levels. The diagnosis of HLH was established 
by the 2004 diagnostic criteria [1]. The patient fulfilled 6 
out of 8 criteria, 5 are considered sufficient for diagnosis 
(fever, splenomegaly, cytopenia of two lineages, hyper-
triglyceridemia and hypofibrigenemia, elevated sIL-
2Receptor and hyperferritinemia). The absence of single 
clinical features, even a negative bone marrow biopsy, 
does not exclude HLH [1]. Other authors have proposed 
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alternative diagnostic criteria such as the HScore, 
because the aforementioned HLH criteria were specifi-
cally developed for the pediatric population and other 
common laboratory findings such as elevated LDH, ele-
vated liver enzymes, hepatic dysfunction and coagulopa-
thy were not considered [5]. The HScore uses additional 
values such as immunosuppression, transaminases and 
LDH to calculate a probability score between 0 and 337 
with values > 167 to classify > 90% of secondary HLH [5]. 
Our patient had an HScore of 267 indicating a 99% prob-
ability of HLH.
Glomerular TMA compatible with renal involvement 
was confirmed by renal allograft biopsy. Complement 
consumption, hypertension as well as seizures can be 
explained by aHUS, since EEG and MRI did not hint at 
an alternative diagnosis. Increasing albuminuria reflects 
glomerular damage. Cases of TMA triggered by PVB19 
infection in both healthy and immunocompromised 
Fig. 1 Characteristic histological findings in the renal biopsy. A-C: A Tubular atrophy and interstitial fibrosis with mild lymphoplasmacellular 
interstitial inflammation and acute tubular damage; no peritubular capillaritis, no eosinophils. B,C: Glomerular thrombotic microangiopathy (TMA) 
with swelling of endothelia cells, lumen obliteration, influx of inflammatory cells, some double contours of the basement membrane and some 
fibrin within glomerular capillaries (B, arrow). PAS staining, magnifications × 10 (A), × 20 (B) and × 40 (C). D-F Immunohistochemical findings: 
Granular mesangiocapillary immune deposits of IgA (D), IgG (E) and most prominently C3c (F) indicating a parainfectious glomerulonephritis. G-J 
Electron micrographs of different magnification showing the characteristic ultrastructural changes in thrombotic microangiopathy, e.g. endothelial 
cell swelling with subendothelial cleft formation and some podocyte damage. No specific osmiophilic deposits, no fibrils. G: × 2000, H: × 5000, J: 
× 8000
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Table 1 Laboratory findings during hospitalization
Normal range Day 1 Day 13 Day 14 Day 16 Day 36
Creatinine (mg/dl) 0.5–0.9 3.2 3.7 4.1 3.7 2.3
Urea (mg/dl) 17–48 137 70 143 166 110
CRP (mg/l) <  0.5 4.4 21.5 29.2 19 2.6
Bilirubin (mg/dl) <  1.2 0.2 4.1 2.1 0.8 0.5
Alanine aminotransferase (U/l) <  31 12 300 201 121 85
Aspartate aminotransferase (U/l) <  35 13 249 143 43 35
Lactate dehydrogenase (U/l) 135–250 203 679 974 763 454
Serum ferritin (μg/l) 13–150 324 2644 20,659 2563 194
Haptoglobin (g/l) 0.3–2.0 1.6 <  0.1 <  0.1 0.14 <  0.1
C3 (mg/l) 900–1800 550 620 470
C4 (mg/l) 100–400 130 140 80
Triglyceride (mg/dl) <  200 211 255
Fibrinogen (g/l) 1.6–4.0 1.1
Hb (g/dl) 12.0–15.6 5.9 7.4 8.3 7.8 8.8
Leukocytes (n/nl) 3.9–10.5 3.4 3.2 3.1 6.5 6.2
Thrombocytes (n/nl) 150–370 302 187 162 92 91
Reticulocytes (n/nl) 25–105 32 169 145 212
Urinary Albumin/Creatinine (mg/gCrea) <  20 169 5307
Fig. 2 Clinical course, treatment milestones, ferritin levels and parvovirus B19 copies. Red dots indicate parvovirus B19 copies. The viral load was 
under the limit of detection on day 1 and day 3. Viral load declined following treatment with IVIGs. Serologic testing was negative for both IgM and 
IgG on day 1 and positive IgM on day 11, IgG stayed negative. Blue squares show ferritin levels
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patients in the absence of an alternative cause have pre-
viously been reported [6–8]. The diagnosis of the PVB19 
infection was made by both serum and bone marrow 
PCR testing. The results suggested a primary infec-
tion, indicated by the presence of specific IgM and the 
absence of specific IgG. When we tested the patient for 
viral infections on first admission, multiple PCR assays 
for PVB19 were negative. However other authors dem-
onstrated that in some individuals PVB19 infection is 
only detectable in bone marrow samples whereas serum 
diagnostic can still be negative [9, 10]. In our case it is 
likely that PVB19 infection was already ongoing when the 
patient was admitted to our hospital.
Secondary HLH is typically a sequela of infections 
(usually EBV, but also CMV or HIV), rheumatic diseases 
(e.g. systemic lupus erythematosus) or malignancies [2]. 
A few cases of HLH due to PVB19 infection have previ-
ously been described, including one patient who had 
received renal transplantation [7, 10, 11].
Even though the incidence of acute kidney injury in 
HLH is high, the exact pathophysiologic mechanism of 
renal damage in HLH remains unclear and is probably 
multifactorial [12]. It has been proposed that PVB19 
directly infects glomerular endothelium by using the 
same receptor (glycosphinoglipid globoside Gb4) used to 
infect erythroid progenitor cells. Subsequently it causes 
endothelial cell dysfunction or cell death leading to aHUS 
[6, 8]. Other studies suggest that aHUS and nephrotic 
proteinuria may have been caused primarily by HLH and 
only indirectly by PVB19 infection [13, 14]. A disease 
mechanism in HLH might be that high levels of inflam-
matory cytokines (particularly TNFα) can injure podo-
cytes, thereby leading to glomerular collapse and tubular 
necrosis with subsequent proteinuria and renal dysfunc-
tion [13, 14]. Another recently proposed mechanism 
suggests coactivation of interferon gamma and comple-
ment activation as culprit in the evolution of TMA in 
patients with HLH [15]. In our patient the TMA should 
be classified as secondary aHUS triggered by parvovirus 
B19 Infection as well as by concomittant HLH. The risk 
haplotypes revealed by genetic screening display a high 
minor allele frequency in the general healthy population. 
In the absence of pathogenic complement variants they 
do not explain occurrence of aHUS. At most, they may 
have acted as additional disease modifiers in the setting 
of marked complement activation [16] .
A few limitations of our study are important to men-
tion. First, a genetic testing for HLH risk haplotypes as 
well as functional complement assays (AH50; alternative 
pathway hemolytic assays) were not performed in this 
patient. Second, a long-term follow up for several years is 
still missing, therefore we cannot evaluate the likelihood 
of HLH relapses.
Treatment of HLH secondary to PVB19 infection 
in a transplant patient poses a challenge to balance 
immunosuppressive therapy to both address HLH and 
to fight PVB19 infection. In the present case, treat-
ment with dexamethasone was initiated when HLH 
was suspected. After a positive PCR result for PVB19, 
intravenous immunoglobulins were added. Mycophe-
nolat mofetil was discontinued and cyclosporine was 
reduced to a trough level of 50 ng/ml. In contrast to 
current recommendations for secondary HLH, we 
decided to taper dexamethasone relatively fast and 
did not prescribe etoposide [17]. We assumed PVB19 
to be the underlying cause of aHUS. In summary, we 
observed the rare combination of HLH and TMA asso-
ciated with parvovirus B19 that escaped initial PCR 
testing.
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